Nyxoah launches Genio bilateral neurostimulation system in Netherlands
Nyxoah (NASDAQ:NYXH) announced the successful commercial launch of its Genio bilateral neurostimulation system in the Netherlands on Dec. 17, 2025.
Every story in this section, newest first — page 385 of 389.
Nyxoah (NASDAQ:NYXH) announced the successful commercial launch of its Genio bilateral neurostimulation system in the Netherlands on Dec. 17, 2025.
INNOVATE Corp. (NYSE:VATE) said MediBeacon, in which it holds a 44.7% equity stake, has received U.S. Food and Drug Administration approval for its next-generation MediBeacon TGFR System, introducing a reusable sensor intended to broaden access to point-of-care kidney function assessment.
Scorpio Tankers (NYSE:STNG) agreed to sell two of its 2016-built LR2 product tankers for a combined $104.6 million, while simultaneously expanding its fleet with the purchase of two scrubber-fitted newbuildings scheduled to arrive in 2027.
Cardone Ventures, the investment firm led by billionaire Grant Cardone and business partners Brandon and Natalie Dawson, has made an unsolicited, non-binding proposal to acquire PetMed Express (NASDAQ:PETS) for $4.25 per share in cash, implying an equity value of around $89 million.
Rezolve Ai (NASDAQ:RZLV) expects to exceed $17 million in revenue for December 2025, with annual recurring revenue (ARR) set to surpass $200 million by year-end.
HEICO Corporation (NYSE:HEI) announced that its Flight Support Group subsidiary, Wencor, has entered into an agreement to acquire EthosEnergy Accessories and Components, a leading provider of repair services for aeroderivative gas turbine engine accessories.
Monte Rosa Therapeutics (NASDAQ:GLUE) reported encouraging early clinical results for its molecular glue degrader MRT-2359 in combination with enzalutamide, showing pronounced activity in a genetically defined subset of heavily pretreated metastatic castration-resistant prostate cancer (mCRPC).
Tonix Pharmaceuticals (NASDAQ:TNXP) has secured exclusive worldwide rights to TNX-4900, a selective small-molecule Sigma-1 receptor antagonist positioned as a potential new treatment for chronic neuropathic pain.
Kraft Heinz (NASDAQ:KHC) named Steve Cahillane as its next chief executive officer, tapping the former Kellanova chief to guide the food giant through its planned separation into two independently traded companies.
Corteva (NYSE:CTVA), the agricultural technology giant, and Hexagon Bio, a biotechnology company focused on nature-derived therapeutics, announced a multi-million-dollar joint venture aimed at accelerating the discovery of new crop protection solutions.
Cosette Pharmaceuticals said the U.S. Food and Drug Administration has approved its abbreviated new drug application for the first generic version of CIPRO HC, granting the company 180 days of Competitive Generic Therapy exclusivity and ending a more than 27-year stretch without a generic alternative.
Viewbix (NASDAQ:VBIX) agreed to acquire between 85% and 100% of Quantum X Labs in a share-based transaction that brings the company deeper into AI-quantum computing, adding a portfolio of four technology businesses and a patent claiming significant advances in quantum error correction.
Royalty Pharma (NASDAQ:RPRX) said it has acquired a royalty interest in two of Nuvalent’s lead cancer programs for as much as $315 million, adding long-dated exposure to a pair of next-generation tyrosine kinase inhibitors targeting ALK- and ROS1-altered non-small cell lung cancer.
Palvella Therapeutics (NASDAQ:PVLA) said the U.S. Food and Drug Administration has granted Fast Track Designation to QTORIN 3.9% rapamycin anhydrous gel for treating angiokeratomas, a dermatologic condition with no currently approved therapies.
Flowserve Corp. (NYSE:FLS) said it has acquired Greenray Turbine Solutions, a U.K.-based specialist in aftermarket products and services for industrial gas turbines, in a move that broadens its rotating-equipment capabilities and adds recurring revenue tied to mission-critical infrastructure.
Nektar Therapeutics (NASDAQ:NKTR) reported mixed Phase 2b results for rezpegaldesleukin in severe-to-very-severe alopecia areata, showing meaningful clinical activity but narrowly missing the trial’s primary endpoint in the modified intent-to-treat population.
The Brand House Collective (NASDAQ:TBHC) reported another quarter of pressured results as e-commerce declines and margin compression overshadowed gains in store traffic.
ATS Corporation (NYSE:ATS) named Doug Wright as its next chief executive officer, concluding a broad leadership search as the automation and industrial technology company prepares for its next phase of growth.
Pfizer (NYSE:PFE) lowered its 2025 revenue forecast and issued new financial guidance for 2026, projecting modest growth outside of COVID-19 and loss-of-exclusivity products as the drugmaker works through declining pandemic demand and the impact of patent expirations.
BRP (NASDAQ:DOO) named Denis Le Vot as its next president and chief executive officer, marking a major leadership transition as José Boisjoli prepares to retire after guiding the powersports manufacturer for nearly two decades.
Tutor Perini Corp. (NYSE:TPC) won a major U.S. federal construction award that could generate up to $900 million in work over the next seven years, strengthening the contractor’s footprint in the Middle East.
Organigram Global (NASDAQ:OGI), Canada’s leading recreational cannabis producer, reported record fourth-quarter and full-year results for the period ended September 30, 2025.
Got a second for a cookie? 🍪Essential cookies keep Grafa running smoothly. A few optional ones help us see what's working so we can make it better. You're in control — change your mind any time. Cookie policy · Privacy policy